ADVA
20.5.2021 09:02:13 CEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its new compact, low-power edge demarcation solution, giving network operators an easy and cost-efficient route to 10Gbit/s Carrier Ethernet services. The ADVA FSP 150-XG108 Series meets the precise needs of mobile network operators (MNOs) aiming to deliver a faster and more responsive experience by rolling out 5G New Radio equipment at scale. The solution also enables enterprises to affordably extend bandwidth as they push data to the cloud and supports the cost-effective expansion of digitized cable networks. Featuring zero-touch provisioning and 5G timing capabilities, the ADVA FSP 150-XG108 Series is ideal for growing network capacity while reducing footprint, power and cost.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005061/en/
“Today’s MNOs need to be able to seize new revenue opportunities and grow capacity without worrying about increased energy consumption or rack space eating into profitability. That’s where our FSP 150-XG108 Series hits the sweet spot. It provides a quick and seamless way to deploy high-bandwidth Carrier Ethernet services without major cost,” said Christoph Glingener, CTO, ADVA. “Our FSP 150-XG108 Series is engineered for the practical challenges of meeting cloud and 5G demand. It consumes very little power and supports both 1Gbit/s and 10Gbit/s interface speeds in a 1RU footprint. What’s more, with its temperature-hardened design, our FSP 150-XG108 Series removes the need for expensive air-conditioning.”
The ADVA FSP 150-XG108 Series enables network operators to easily and affordably migrate from 1Gbit/s to 10Gbit/s MEF 3.0 services. Using proven and established OAM processes, it offers simple operation and network integration. With zero-touch provisioning, the ADVA FSP 150-XG108 Series removes the need for technically trained onsite staff and makes service activation quick and easy. Its compact design caters for space-restricted applications and its redundant power supply ensures high availability. The ADVA FSP 150-XG108 Series is also well prepared for emerging timing requirements with hardware-assisted BITS, PTP and SyncE synchronization.
“We’re providing the compact, robust and reliable demarcation that mobile, cable and enterprise networks require for massive 10Gbit/s rollout. Our FSP 150-XG108 Series is simple, efficient and highly scalable. With zero-touch provisioning, service activation becomes effortless. The FSP 150-XG108 Series also offers intuitive network control and service monitoring through the automated management of our Ensemble Controller and Ensemble Packet Director,” commented James Buchanan, GM, Edge Cloud, ADVA. “And, despite being optimized for cost-sensitive, high-bandwidth applications, our FSP 150-XG108 Series doesn’t compromise on performance or synchronization. It’s the perfect choice for empowering any network edge with 10Gbit/s demarcation and aggregation.”
Watch this product video for more information: https://youtu.be/pAcqPOtO5eI .
Additional details are also available in this Tech Cam interview: https://youtu.be/bdd-AqvgpBM .
Supporting slides can be viewed here: https://adva.li/fsp-150-xg108-series-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005061/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom